17m
Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke
Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results